Lyra Therapeutics, Inc. (LYRA)
| Market Cap | 1.15M -84.3% |
| Revenue (ttm) | 398.00K -74.1% |
| Net Income | -28.92M |
| EPS | -18.62 |
| Shares Out | 1.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,179 |
| Average Volume | 8,679 |
| Open | 0.7000 |
| Previous Close | 0.7000 |
| Day's Range | 0.6500 - 0.7000 |
| 52-Week Range | 0.3100 - 37.5000 |
| Beta | 0.69 |
| RSI | 39.53 |
| Earnings Date | Aug 7, 2026 |
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients wh... [Read more]
Financial Performance
In 2025, Lyra Therapeutics's revenue was $398,000, a decrease of -74.05% compared to the previous year's $1.53 million. Losses were -$28.92 million, -69.05% less than in 2024.
Financial StatementsNews
Lyra Therapeutics announces intention to file Form 25 for delisting from Nasdaq
Lyra Therapeutics (LYRA) announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission on Monday, April 20, 2026, to remove its…
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securit...
Lyra Therapeutics common stock to be delisted by Nasdaq
On February 2, Lyra Therapeutics (LYRA) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the company that Nasdaq has determined to delist the company’s...
Why Is Lyra Therapeutics Stock (LYRA) Down Today?
Lyra Therapeutics stock was down on Monday after the company revealed a pause to its operations.
Lyra Therapeutics suspends further development of LYR-210
Lyra Therapeutics (LYRA), announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis....
Lyra Therapeutics Provides Corporate Update
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further developm...
Lyra Therapeutics reports Q3 EPS ($3.38), consensus ($4.07)
Reports Q3 revenue $25,000, consensus $154,250. “We are now focused on putting all the components in place for a new, confirmatory Phase 3 clinical trial to make progress toward a…
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission –
Lyra Therapeutics announces clinical plan for LYR-210
Lyra Therapeutics (LYRA) announced the Company’s clinical plan and upcoming oral presentation of results from the positive Phase 3 ENLIGHTEN 2 trial for LYR-210, the company’s lead product candidate f...
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 20...
Lyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78)
Reports Q2 revenue $183,000, consensus $181,250. “The positive results from our ENLIGHTEN 2 trial have enabled us to secure financing and are providing momentum to optimize our regulatory strategy and...
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-2...
Lyra Therapeutics files to sell 846,744 shares of common stock for holders
17:16 EDT Lyra Therapeutics (LYRA) files to sell 846,744 shares of common stock for holders
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants Upfront Gross Proceeds of $5...
Lyra Therapeutics target adjusted to $16 from $2 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Lyra Therapeutics (LYRA) to $16 from $2 and keeps a Neutral rating on the shares following the company’s reverse stock split. Published…
Lyra Therapeutics Stock (LYRA) Rockets 530% on Phase 3 Trial Results
Lyra Therapeutics stock took off on Monday as investors reacted to positive Phase 3 clinical trial results.
Lyra Therapeutics Transcript: Study Result
Enlightened II phase III trial of LYR-210 in CRS met primary and key secondary endpoints, showing significant symptom and quality-of-life improvements with a strong safety profile. Plans are underway for FDA engagement and further studies in polyp patients.
Lyra Therapeutics says ENLIGHTEN 2 trial of LYR-210 met primary endpoint
Lyra Therapeutics (LYRA) announced results from the ENLIGHTEN 2 Phase 3 clinical trial of LYR-210 in adult patients with CRS. The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210…
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
WATERTOWN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory s...
Lyra Therapeutics trading halted, news pending
19:50 EDT Lyra Therapeutics (LYRA) trading halted, news pending
Lyra Therapeutics to present results from ENLIGHTEN 1 Phase 3 study
Lyra Therapeutics (LYRA) announced that the Company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 Phase 3 study for LYR-210, the Company’s lead product candidate…
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory s...
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – – Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic...
Lyra Therapeutics reports Q4 EPS ($1.43), consensus (13c)
Cash and cash equivalents as of December 31 were $40.6M compared with cash, cash equivalents and short-term investments of $51.6M at September 30. Based on our current business plan, we…
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory...